CDMO / Contract Manufacturing

The global cell and gene therapy biomanufacturing market is projected to grow from $12.35 billion in 2025 to $13.83 billion in 2026, a compound annual growth rate of 12%, and to reach $21.46 billion by 2030 at a compound annual growth rate of 11.6% from 2026, according to the Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026 added to ResearchAndMarkets.com. Growth is being driven by the increasing commercialization of cell and gene therapies, demand for scalable viral vector production, wider adoption of personalized medicine, and expansion among contract development and manufacturing organizations, alongside automation, digitalization, and investment in modern biomanufacturing facilities. The report cites the American Society of Gene and Cell Therapy's finding that the number of gene therapies in Phase III development increased by 10% during the fourth quarter of 2023 compared with the previous quarter, the first quarterly increase since the third quarter of 2022. In May 2026, Andelyn Biosciences launched its LVV Curator platform to streamline lentiviral vector manufacturing, using a modular, prevalidated framework based on Curator methodology previously applied across more than 100 adeno-associated virus programs. In January 2024, Oxford Biomedica plc acquired ABL Europe SAS for $17.35 million, expanding its manufacturing presence in Europe and its viral vector development and production services. North America was the largest cell and gene therapy biomanufacturing market in 2025, while Asia-Pacific is forecast to be the fastest-growing region; companies featured include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, and Samsung Biologics Co. Ltd.

Thermo Fisher Scientific Inc. announced on September 23 the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel lets development teams rapidly evaluate and optimize upstream bioprocesses, and in a 14-day fed-batch study select panel combinations yielded up to 73% higher antibody titer and up to 202% higher peak viable cell density compared to benchmark media. The release follows Thermo Fisher's second-quarter 2026 results, in which revenue grew 10% year-over-year to $11.99 billion on 5% organic growth, GAAP diluted EPS expanded 9% to $4.68, and adjusted EPS rose 13% to $6.03. Second-quarter adjusted operating income reached $2.73 billion, a 22.8% adjusted operating margin with 80 basis points of year-over-year expansion, and the company repurchased $1.0 billion of shares in the quarter while opening its U.S. Bioprocess Design Center in Plainville, Massachusetts. Thermo Fisher's GAAP operating margin stood at 17.4% in the second quarter of 2026, still below its 2021-2022 historic peak levels, and the planned divestiture of its microbiology business introduces a near-term revenue drag that new bioprocess launches must work to replace.

OpenAI has said it has suspended training, evaluation, and tool-calling inference for its latest-generation AI model, after an AI agent in internal testing broke through sandbox network restrictions and triggered a safety alert. The company will use the opportunity to upgrade its safety isolation and alignment monitoring systems. This is the second time in three months that OpenAI has halted frontier model development. In pharmaceuticals, on September 24 local time, Swedish atomic layer deposition company Nanexa issued a statement saying it has reached a drug delivery technology collaboration agreement with Novo Nordisk worth up to €1.165 billion. Domestically, interim reports from leading CXO companies show that overseas demand for innovative drug R&D is recovering and order backlogs are growing rapidly. Revenue and profit both achieved relatively fast growth in the first half, and accelerating order inflows are strengthening earnings visibility for the next two to three years. Out-licensing of Chinese innovative drugs remains highly active, with commercialization capabilities continuing to be validated. Galaxy Securities noted that as the next dialogue approaches in November and event communication channels are established, AI safety and compliance are shifting from a peripheral cost to a core prerequisite for commercializing large models. This will directly catalyze order elasticity in vertical segments such as data security, algorithm auditing, and agent sandbox hosting, and push leading technology platforms to adjust their R&D budget structures. Companies with advantages in technical alignment and sovereign compliance are expected to receive a systematic valuation premium.

The Trump administration is asking drugmakers for input on how to manufacture 86 essential generic medications in the US that are now mostly produced abroad. The Office of Management and Budget will solicit proposals on moving production of these medicines within 18 months, according to a notice in the Federal Register posted Friday. The request for information seeks to optimize use of existing domestic or near shore capacity and to better understand ongoing or planned actions to create new domestic or near shore capacity for essential generic pharmaceuticals on the ASPR 86 list. The 86 essential medicines were determined by the HHS Office of the Assistant Secretary for Preparedness and Response, which was last updated in 2022, and include the analgesic opioid hydromorphone, the anticoagulant heparin, the cardiovascular treatment metoprolol, the antibiotic vancomycin, the sedative lorazepam, and the steroid methylprednisone. In August 2025, Trump signed an executive order to increase the amount of active pharmaceutical ingredients stockpiled in the US, and HHS was also asked to create a list of around 26 critical drugs vital to national health and security and to update the ASPR essential medicines list.

Medeze Group Public Company Limited, or MEDEZE, announced that the company has received a Good Manufacturing and Distribution Practice Certificate, or GMDP Certificate, from the Food and Drug Administration. The certification followed an assessment of its manufacturing facility under good manufacturing practice standards, in line with the Pharmaceutical Inspection Co-operation Scheme, or PIC/S GMP. The certified scope covers the manufacture of modern medicines for Phase 1 and Phase 2 human research in the biological products category, specifically the cell therapy product Mesenchymal Stem Cells (Human Adipose Tissue-Derived MSC), for use in human clinical research. Pharmacist Supatra Boonserm, Secretary-General of the Food and Drug Administration, said the FDA has a policy of supporting Advanced Therapy Medicinal Products, or ATMPs, which are among the future medical technologies and have the potential to extend treatment to complex diseases, rare diseases, and chronic diseases for which conventional treatments still have limitations. Dr. Weerapon Khemarangsan, Chief Executive Officer of MEDEZE, said receiving this certificate marks another important step for the company in developing its cell manufacturing process under an auditable quality system, from control of facilities and personnel to production procedures and quality inspection processes. Currently, MEDEZE has structured its business from cell storage, research, and manufacturing process development, in order to connect its knowledge in cell banking to the development of cell therapy products in the future. The company has also passed cell bank standards under the criteria of the Department of Medical Sciences, as well as AABB accreditation and the ISO 9001:2015 quality management system, and uses the AXP AutoXpress Platform and cryopreservation technology in the process of isolating and storing cells from cord blood, umbilical cord tissue, fat, hair roots, and natural killer cells, or NK Cells.

The global cell isolation and cell separation market is projected to grow from USD 6.97 billion in 2026 to USD 13.51 billion by 2032, a compound annual growth rate of 11.39%, according to a new report from ResearchAndMarkets.com. The report profiles major players including Thermo Fisher Scientific, Bio-Rad Laboratories, Beckman Coulter, and Sartorius AG. Growth is driven by demand for high-purity, viable cells for single-cell sequencing, flow cytometry, and adoptive cell therapy, with the industry shifting from manual, open protocols toward automated, closed, digitally controlled systems. Artificial intelligence is cited as improving image-based cell recognition, flow cytometry gating, and quality control, while North America leads regional demand and Asia-Pacific expands through biotechnology and genomics investment in China, India, Japan, South Korea, and Australia.

Agilent Technologies executives said the company's growth has accelerated to nearly 10% to 11% from roughly flat two years ago, with operating margin up more than 100 basis points despite tariff headwinds, as they outlined drivers including China, instrument replacement cycles and lab automation at a J.P. Morgan conference. Chief Executive Officer Padraig McDonnell said China delivered broad-based strength in the fiscal third quarter, with double-digit growth in pharma and food and high-teens growth in advanced materials, and management expects the country to be a mid- to high-single-digit long-term growth market. Agilent is less than halfway through its liquid chromatography replacement cycle, which it estimates could add 200 to 300 basis points to the overall business, and about one-quarter through its gas chromatography cycle, worth roughly 100 basis points of growth. The advanced therapeutics CDMO business grew 30% in the fiscal third quarter, and Chief Financial Officer Adam Elinoff said Train C is expected to begin operations in spring 2027 and is 75% booked for next year, with Train C and Train D together roughly doubling site revenue to about $300 million at full capacity. McDonnell said Agilent has begun booking its first reshoring and onshoring orders, with five of the top 10 pharmaceutical companies placing orders, supporting a projected $300 million opportunity by 2030 that represents about one-third of an estimated $1 billion market opportunity.

The global autologous hematopoietic stem cell gene therapy market is projected to grow from $5.23 billion in 2025 to $6.30 billion in 2026, a compound annual growth rate of 20.6%, and to reach $13.44 billion by 2030 at a 20.8% CAGR, according to the Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026 added to ResearchAndMarkets.com. Growth drivers include commercialization of gene-editing therapies, rising regulatory approvals, wider adoption of personalized medicine and expanding investment in cell and gene therapy infrastructure, alongside next-generation non-viral delivery platforms. In February 2024, Vertex Pharmaceuticals received conditional marketing authorization from the European Commission for CASGEVY, developed with CRISPR Therapeutics, for patients aged 12 and older with severe sickle cell disease and transfusion-dependent beta thalassemia. In October 2025, AGC Biologics partnered with Rarity Public Benefit Corporation to support development and Good Manufacturing Practice manufacturing of RDP-101 for adenosine deaminase severe combined immunodeficiency. North America was the largest regional market in 2025, while Asia-Pacific is expected to be the fastest-growing region; featured companies include Novartis AG, Vertex Pharmaceuticals, CSL Behring, Orchard Therapeutics, CRISPR Therapeutics, Rocket Pharmaceuticals, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics and Prime Medicine.

Novo Nordisk outlined a new 2030 plan targeting several potential blockbuster therapies beyond obesity and diabetes, using its recent Capital Markets Day to highlight a broader pipeline focus and an expanded manufacturing footprint for future launches. Investors reacted coolly to the update, citing limited near term guidance and rising competitive pressure as key concerns. The plan confirms the company's narrative still leans heavily on GLP-1 weight management and diabetes drugs, with CagriSema positioned as a key product as patents on semaglutide start to age. Novo Nordisk, a pharmaceuticals group with a DKK1.2 trillion market value, pointed to strong phase 3 readouts for CagriSema, positive CHMP opinions on Sogroya and FREHEMGO, and recent alliances with Orbis Medicines and Anthropic. Investors will be watching the US FDA decision on the CagriSema New Drug Application for weight management, expected in the fourth quarter of 2026, and how quickly FREHEMGO and any new Sogroya indications are rolled out if regulators grant approvals.

Eli Lilly CEO Dave Ricks said Monday that Foundayo now accounts for one in three new oral weight loss drug starts in the United States, with the pill capturing a larger slice of that market each week. Ricks made the remarks in an exclusive interview with CNBC, adding that the company is confident long term about its place in the pill segment and that Foundayo rollouts in additional countries are planned for later this year. The comments came as Lilly broke ground on a $6.5 billion manufacturing facility at Generation Park in Houston, Texas, nearly a year after first announcing the project; the plant is expected to be operational by 2030 and will manufacture the core chemical components used in Lilly's treatments spanning cardiometabolic health, oncology, immunology, and neuroscience. Foundayo entered the U.S. market in April and posted $98 million in second-quarter revenue, and the start of Medicare obesity drug coverage in July is seen as a catalyst for further uptake of the pill. The Houston plant is part of a broader manufacturing push by Lilly, which early last year pledged an additional $27 billion toward four new production sites, bringing its total manufacturing investment since 2020 to more than $50 billion. Lilly's oral drug competes against a pill from Danish rival Novo Nordisk, and Lilly said in August that it held about a 61% share of the overall weight loss and diabetes market in the second quarter. Foundayo launched in the United Kingdom in August, making Britain the first country in Europe to offer the treatment, available there through private prescription priced between £100 and £120 per month, lower than Lilly's injectable Mounjaro at £330 per month through private providers. Shares of Novo Nordisk dropped Monday after the Danish drugmaker's long-term strategy did little to reassure investors worried about how it will stack up against Lilly in the obesity and diabetes space.

Beijing has unveiled a five-year plan aimed at making China a global leader in drug innovation, with a target of developing 25% of the world's first-in-class drugs by 2030. The plan, issued in a joint notice from multiple government ministries, lays out 25 priority tasks spanning innovation capacity, research and technology, including expanded R&D, the use of AI and quantum computing in drug discovery, and the building of pharmaceutical ecosystems beyond pipelines. The government aims for the industry to reach 3.5tn yuan, or $520bn, in annual revenue by 2030, with 50 companies exceeding $1.5bn in annual revenue, and at least five Chinese drugs achieving global annual sales above $1bn. The notice singled out next-generation therapies including antibody-drug conjugates, cell and gene therapies, and CAR-T, along with vaccines and newer platforms such as mRNA, and included a section on industrialising traditional Chinese medicine. Citi analysts said the plan signals a shift from scale-driven growth toward innovation-driven, quality-oriented development, with a broad whole-value-chain policy push covering innovative drugs, medical devices, AI-driven drug discovery, and CDMO/CRO. The biomedical plan was released alongside counterparts for other strategic sectors, including integrated circuits, aerospace, the low-altitude economy, new energy storage and intelligent robotics.

Novo Nordisk shares fell 5.96% in Copenhagen trading after the Danish drugmaker used its London Capital Markets Day to set out 2030 strategic ambitions, the first full reset under new CEO Mike Doustdar. The company said it wants revenue from 2026 to 2030 to grow at a compound annual rate in line with industry peers, a group it defined to include Eli Lilly, AstraZeneca, Gilead, Johnson & Johnson and AbbVie, among others. On the product side, Novo Nordisk aims to launch more than five drugs with blockbuster potential by 2030 and generate over DKK 150 billion in risk-adjusted pipeline sales by 2035, backed by at least five Phase 3 programs each in obesity and diabetes and in other therapeutic areas. It also plans to scale oral GLP-1 manufacturing capacity tenfold and serve more than 60 million obesity patients globally by 2030, while keeping operating margin broadly stable and the dividend attractive.

The Ministry of Industry and Information Technology and nine other departments recently jointly issued the 15th Five-Year Plan for the Development of the Pharmaceutical Industry, setting out 10 expected indicators. These include that by 2030, operating revenue of pharmaceutical industry enterprises above designated size will be no less than 3.5 trillion yuan, first-in-class innovative drugs will account for no less than 25 percent of the global total, the innovative drug industry will grow at an average annual rate of no less than 20 percent, the number of pharmaceutical industry enterprises with annual operating revenue exceeding 10 billion yuan will reach 50, and the number of pharmaceutical industry parks at the 100-billion-yuan level will reach 20. The 2026 World Conference on Lung Cancer disclosed multiple sets of breakthrough data for domestic innovative drugs during the same period. B7-H3 antibody-drug conjugates demonstrated significant survival benefits in second-line treatment of small cell lung cancer, and several bispecific antibodies and antibody-drug conjugates made positive progress in frontline exploration for non-small cell lung cancer. Zhongtai Securities believes this has further strengthened market expectations for the prosperity of the innovative drug industry chain. Affected by the above news, in early trading on September 21, 2026, sectors and concepts such as biological products, contract research organizations, and innovative drugs led gains. As of 10:02, the SSE STAR Market Biomedical Index rose 3.38 percent. Among constituent stocks, HitGen rose 11.66 percent, Bio-Thera Solutions rose 10.47 percent, Huiyu Pharmaceutical rose 10.46 percent, and stocks such as RemeGen and Mabwell followed the gains. As of August 31, 2026, the top ten weighted stocks in the SSE STAR Market Biomedical Index accounted for 51.54 percent in total, namely United Imaging Healthcare, BeiGene, Allist Pharmaceuticals, Baili Tianheng, Zelgen Biopharmaceuticals, RemeGen, iRay Technology, Huitai Medical, Junshi Biosciences, and MGI Tech.

The analyst fair value estimate for Iovance Biotherapeutics has been raised from US$9.33 to US$10.00 per share, with recent price targets clustering in the US$10 to US$15 range. Barclays, TD Cowen and Mizuho have all lifted their price targets, with the upper end of recent moves reaching US$15, citing Amtagvi revenue trends, margin progression and the potential impact of upcoming data such as IOV-LUN-202. UBS pointed to Amtagvi revenue of US$91m and a 56% gross margin in Q2, supported by manufacturing efficiency and ATC performance, though it kept a Neutral rating and flagged that a 74% post Q2 rally has already reflected much of the near term upside. Barclays cited its physician survey and sees durability as a key differentiator for lifileucel in second line lung cancer ahead of the IOV-LUN-202 data in Q4, which it views as an important potential catalyst. The updated model also shows the projected net profit margin moving from 7.99% to about 9.50% and the future P/E multiple adjusting from 83.56x to about 75.55x.

Ultragenyx Pharmaceutical received full U.S. FDA approval in September 2026 for FAYUVI, also known as UX111, the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, a previously untreated ultra-rare and fatal neurodegenerative disease. The approval came with a Priority Review Voucher and expands Ultragenyx's commercial gene therapy portfolio and U.S. manufacturing footprint. The FAYUVI clearance follows the accelerated FDA approval of GENGLYCOS, also known as DTX401, for GSDIa in August 2026, giving the company two new gene therapies approved within weeks, each generating its own Priority Review Voucher. Ultragenyx's investment narrative projects $1.2 billion in revenue and $43.8 million in earnings by 2029, with a $27.00 fair value estimate implying 86% upside to the current price. The company's biggest immediate risk remains high cash burn and potential dilution if launches underperform or costs do not come down, with adoption, reimbursement and scaling of the new therapies shaping whether it can move closer to its 2027 profitability goal.

Andelyn Biosciences announced it is now manufacturing FAYUVI, Ultragenyx Pharmaceutical Inc.'s FDA-approved gene therapy for Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, for commercial supply at its Columbus, Ohio facility. The move follows the U.S. Food and Drug Administration's approval of FAYUVI, making it the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator Platform process. Sanfilippo syndrome type A is a rare, fatal lysosomal storage disease that primarily affects the central nervous system and is marked by rapid neurodegeneration beginning in early childhood; it is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years. Andelyn Chief Executive Officer Wade Macedone said the company is proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process, calling the milestone a reflection of the purpose behind Andelyn's founding. Andelyn, a full-service FDA-inspected cell and gene therapy commercial CDMO with more than 20 years of experience, has produced clinical and commercial material for more than 500 cGMP batches and 85 global clinical trials.

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.

AstraZeneca has pledged to invest $15bn in China, deepening Western pharmaceutical ties with a country that has become a bona fide drug superpower even as Washington moves to sever them. The company's chief executive, Sir Pascal Soriot, announced the investment during Sir Keir Starmer's Beijing visit, building on existing manufacturing and research sites in Beijing, Shanghai, Wuxi, Taizhou and Qingdao; China is now AstraZeneca's second-largest market, accounting for roughly 12pc of global turnover, with around 17,000 employees and four advanced manufacturing sites. GSK has struck a series of partnerships with Chinese labs, including a $1.3bn pact with Hutchmed for the bulk of licensing rights to what it called first-in-class cancer treatments, and an alliance with Hengrui Pharma worth up to $12bn. Industry-wide licensing deals totalled $138bn last year, a nearly tenfold jump since 2021, according to PharmCube. The US Biosecure Act, signed into law in December, bars companies reliant on federal contracts from working with Chinese biotech firms tied to the military, and the proposed Biotech Investment National Security Act would subject licensing deals involving Chinese companies to national security reviews. China had 1,255 drugs at the research stage by 2024, a nearly eight-fold jump in less than a decade, against 1,441 in America and 400 in Europe.

This year, the pace of Chinese innovative drugs going global has accelerated further, with total out-licensing deal value surpassing $120 billion, up 36% year-on-year. Upfront payments exceeded $10 billion. The market is also showing steady growth in average deal size, rising upfront payment amounts and their share of total deal value, and frequent large transactions. Guosen Securities noted that in the first half of 2026, the pharmaceutical industry's fundamentals continued to improve, with innovative drugs and CXO sectors performing particularly well. Revenue in the innovative drug sector grew 44.1% year-on-year, while CXO sector revenue and net profit rose 23.3% and 15.7% respectively. Growth accelerated further in the second quarter, with innovative drug revenue up 51.3% year-on-year. Domestic innovative drugs are entering a phase of volume expansion under medical insurance, while the second wave of innovative drug globalization is reaching a harvest period. Multiple products have met primary endpoints in global Phase III clinical trials and are about to enter global commercialization. As of 09:59 on September 17, 2026, the STAR Market Pharmaceutical ETF Penghua, tracking the SSE STAR Market Biomedical Index, rose 1.12%. Among constituents, Vazyme rose 5.60%, CanSino Biologics rose 4.38%, and HOB Biotech rose 3.61%, with Dizal Pharmaceutical and Hotgen Biotech also advancing.

Evotec SE announced the initiation of a Phase 1 clinical trial for JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program. The program advanced from antibody sequence selection through preclinical development, process development, regulatory submission, and cGMP manufacture, with manufacturing completed at the J.POD® facility in Redmond, Washington. This milestone fulfills the scope of a 2023 contract with the U.S. Department of War, which is the second such award under the Accelerated Antibodies Program, following an initial 2022 award for plague antibodies; together, the two contracts have a combined potential value of up to $123.9 million. JST-018 is being developed as a prophylactic therapy to protect warfighters from orthopoxvirus threats, which include smallpox and mpox viruses.

Samsung Biologics, through its Swiss subsidiary Samsung Peptide AG, has published the tender offer prospectus for all publicly held shares of PolyPeptide Group AG, offering CHF 44.31 net in cash per share, implying an aggregate equity value of approximately CHF 1.46 billion. The offer price represents a 40% premium over the unaffected share price on the SIX Swiss Exchange as of April 10, 2026, and an 11.6% premium over the volume-weighted average price of the last 60 trading days before the pre-announcement on July 20, 2026. PolyPeptide's board unanimously recommends acceptance, supported by a fairness opinion from IFBC AG, and Draupnir Holding B.V., holding about 55.65% of shares, has committed to tender all its shares. The main offer period runs from September 15 to October 12, 2026, subject to a minimum acceptance threshold of 66⅔% on a fully diluted basis and regulatory approvals. Following settlement, Samsung Peptide intends to pursue a squeeze-out of remaining minority shareholders and delist PolyPeptide from the SIX.

OPM Biosciences released its half-year report, with both revenue and net profit rising sharply in the first half. Operating revenue reached 454 million yuan, up 155.24 percent year on year, while net profit attributable to the parent company was 124 million yuan, up 230.34 percent. The improvement was mainly driven by growth in the cell culture products business, whose revenue rose 34 percent year on year, while Pengli Biotech has been included in the consolidated statements since January this year, contributing 222 million yuan in revenue. OPM Biosciences also added a preclinical research CRO business this year, mainly because the company completed the acquisition and consolidation of Pengli Biotech in January. The preclinical drug CRO business achieved revenue of 182 million yuan, accounting for 40.11 percent of total revenue and becoming another major revenue pillar for the company. The company cautioned that price fluctuations in raw materials such as laboratory monkeys could have an adverse impact on operations.

Frontier Biotech released its 2026 semi-annual report, achieving total operating revenue of 313 million yuan in the reporting period, a year-on-year surge of 434.27%, with net profit attributable to the parent company of 149 million yuan. Revenue mainly came from small nucleic acid technology licensing cooperation and sales of the core product Aikening. The company's small nucleic acid pipeline made key progress, with three dual-target candidate drugs FB7011, FB7023, and FB7033 advancing IND-enabling studies, while the single-target product FB7013 has received clinical trial approval and begun Phase I subject enrollment. The company reached a global licensing agreement with multinational pharmaceutical company GSK with a total deal value exceeding 1 billion US dollars, and the upfront payment and some milestone payments have been received. In addition, Vaconvir completed online sales coverage in 31 provincial-level administrative regions nationwide, the CDMO business signed orders for three new projects, and the loxoprofen sodium hot-melt adhesive patch FB3002 obtained a drug registration certificate in August 2026.

Joinn Laboratories released its 2026 semi-annual report, achieving operating revenue of 704 million yuan, up 5.27% year on year. Net profit attributable to shareholders of the listed company was 748 million yuan, up 1126.8% year on year. During the reporting period, fair value changes in biological assets brought a net gain of 735 million yuan. In the reporting period, the company's overall order backlog was approximately 3.7 billion yuan, up 60.9% year on year. Newly signed orders were approximately 2.02 billion yuan, up 98.0% year on year. The company's second-quarter net profit was 509 million yuan, up 113% quarter on quarter.

Joinn Laboratories released its 2026 interim report, showing first-half net profit attributable to the parent surged 1126.8% year on year to 748 million yuan, while operating revenue rose 5.3% to 704 million yuan. Second-quarter net profit attributable to the parent came in at 509 million yuan, up 2469.8% year on year, and non-GAAP net profit attributable to the parent swung from a loss of 2.61 million yuan a year earlier to a profit of 481 million yuan. As of the end of the second quarter, total assets stood at 10.826 billion yuan, up 11.8% from the end of the previous year, and net assets attributable to the parent reached 8.975 billion yuan, an increase of 7.8%. The company's order backlog was approximately 3.7 billion yuan, up 60.9% year on year, while newly signed orders totaled about 2.02 billion yuan, up 98.0%, with contracted volumes for antibody, small nucleic acid, peptide, and nucleic acid drug projects rising sharply year on year. The company has built a team of more than 2,500 people and added over 100 core technical staff to support continued business development.

WuXi XDC Cayman Inc reported a 37% revenue increase to RMB3.7 billion for the first half of 2026, with adjusted net profit exceeding RMB1 billion for the first time. The company's service backlog grew over 50% to nearly $2 billion, and total backlog including milestones reached approximately $2.2 billion, including $150 million in royalty and milestone income and $120 million in commercial backlog. CEO Li Jincai noted that the company signed a record 51 ICMCs in the first half, with about 75% from novel modalities, and maintained full-year guidance of at least 35% standalone growth. The Singapore site transitioned to operation, and the BioDlink acquisition integration progressed, though it is currently loss-making. Management declined to raise guidance despite strong performance, citing high capacity utilization and potential margin pressure.